Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | HMGCR | P04035 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12845585 | 0.77 | TAAR1 (0.65) | HTR2ACYP3A4KDM4ECYP19A1ALDH1A1 | |
| SCHEMBL30600118 | 0.77 | TAAR1 (0.65) | HTR2ACYP3A4KDM4ECYP19A1ALDH1A1 | |
| SCHEMBL900875 | 0.76 | CYP3A4 (0.48) | HTR2ACYP3A4KDM4ECYP19A1ALDH1A1 | |
| SCHEMBL7955089 | 0.75 | HTR2A (0.52) | HTR2ACYP3A4KDM4ECYP19A1ALDH1A1 | |
| SCHEMBL1886751 | 0.75 | HTR2A (0.52) | HTR2ACYP3A4KDM4ECYP19A1ALDH1A1 | |
| SCHEMBL900127 | 0.75 | HTR2A (0.52) | HTR2ACYP3A4KDM4ECYP19A1ALDH1A1 | |
| SCHEMBL774974 | 0.75 | HTR2A (0.57) | HTR2ACYP3A4KDM4ECYP19A1ALDH1A1 | |
| SCHEMBL2340417 | 0.75 | HTR2A (0.52) | HTR2ACYP3A4KDM4ECYP19A1ALDH1A1 | |
| SCHEMBL17394562 | 0.75 | HTR2A (0.52) | HTR2ACYP3A4KDM4ECYP19A1ALDH1A1 | |
| SCHEMBL95746 | 0.75 | PDE4A (0.64) | HTR2ACYP3A4KDM4ECYP19A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | ENERGENESIS BIOMEDICAL CO., LTD (TW) | 2014-10-09 | — | — | US | disclosed |
| EP-2430036-B1 | SUBSTITUTED 6-(BENZYLAMINO) PURINE RIBOSIDE DERIVATIVES, USE THEREOF AND COMPOSITIONS CONTAINING THESE DERIVATIVES | Univerzita Palackého v Olomouci (CZ) | 2014-07-30 | — | — | EP | disclosed |
| US-20140066394-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | BIOPATTERNS, S.R.O (CZ) | 2014-03-06 | — | — | US | disclosed |
| US-20120071433-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | UNIVERZITA PALACKEHO V OLOMOUCI (CZ) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066394-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | PNP, NUDT1, TYMP | HTR2A 2455/4885CYP3A4 4358/4885KDM4E 3704/4885 |
| US-20140303112-A1 | Method for treating disease or condition susceptible to amelioration by AMPK activators and compounds of formula which are useful to activate AMP-activated protein kinase (AMPK) | PRKAG2, PRKAB2, PRKAG1 | HTR2A 3798/4885CYP3A4 4016/4885KDM4E 3951/4885 |
| US-20120071433-A1 | Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives | CD38, NUDT1, PNP | HTR2A 2574/4885CYP3A4 4487/4885KDM4E 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.